购物车
- 全部删除
- 您的购物车当前为空
KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.
KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | |
50 mg | ¥ 13,800 | 6-8周 | |
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines. |
体外活性 | KU14R partially attenuated responses to Imidazole-4-acetic acid-ribotide (IAA-RP). Insulin Receptor A new I(3)-R antagonist, KU14R (2 (2-ethyl 2,3-dihydro-2-benzofuranyl)-2-imidazole), which selectively blocks the insulin secretory response to imidazolines. By measuring KATP channel activity, plasma membrane potential, cytosolic calcium concentration ([Ca2+]c), and dynamic insulin secretion to compare the effects of KU14R on stimulus secretion-coupling in normal mouse islets and beta cells. KU14R (30, 100 or 300 micromol/l) was ineffective, in the presence of 10 mmol/l but not of 5 mmol/l glucose. KATP channel was blocked by KU14R (IC50 31.9 micromol/l, Hill slope -1.5). KU14R does not act as an antagonist of either efaroxan or S22068 at an imidazoline site in vivo. |
分子量 | 214.26 |
分子式 | C13H14N2O |
CAS No. | 189224-48-4 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.